ScreenerHero

MLYS Mineralys Therapeutics, Inc.

NAS · US · Healthcare · Biotechnology · mineralystx.com
22.09USD+0.64%Mkt Cap: 1.95B $P/E: —

Mineralys Therapeutics, Inc., a biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. It is developing lorundrostat, a proprietary, orally administered,…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap1.95B USD
Enterprise Value1.38B USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-154.65M USD
Revenue/Share—
Last Price22.09 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees76
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-8.78
PEG—
EV/EBITDA-3.71
EV/Revenue—
P/S—
P/B3.52
EPS (TTM)-4.22
EPS (Forward)-2.50
52W Range
21.502% of range47.65
52W High47.65 USD
52W Low21.50 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-23.91%
ROA-23.37%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-142.42M USD
CapEx (TTM)15.00K USD
FCF Margin—
FCF Yield-10.45%
Net Debt-563.79M USD
Net Debt/EBITDA1.52
Balance Sheet
Debt/Equity17.72
Current Ratio34.46
Quick Ratio34.24
Book Value/Sh6.24 USD
Cash/Share7.48 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)48.50 USD
Upside (mean)+119.6%
Target Range30.00 USD – 56.00 USD
30.00+119.6% to mean56.00
# Analysts8
Ownership
Shares Out.88.16M
Float66.60M
Insiders0.70%
Institutions117.61%
Short Interest
Short Ratio8.0d
Short % Float12.43%
Short % Out.10.39%
Shares Short9.18M
Short (prev mo.)9.65M
Technical
SMA 5026.79 (-17.5%)
SMA 20028.36 (-22.1%)
Beta0.69
S&P 52W Chg16.45%
Avg Vol (30d)1.31M
Avg Vol (10d)1.35M
Technical Indicators
RSI (14)31.3
MACD-1.2904
MACD Signal-0.6880
MACD Hist.-0.6024
BB Upper32.17 USD
BB Middle26.60 USD
BB Lower21.03 USD
BB Width41.88%
ATR (14)1.414 USD
Vol Ratio (20d)0.67x